CSK and metastatic prostate carcinoma: Staining of the prostate cancer progression panel with this validated antibody revealed a significant decrease in average CSK reactivity in metastatic prostate cancer and CRPCs relative to primary prostate cancers (Figure 5B, Supplementary Figure S5B).